Oncotelic Therapeutics, Inc.
OTLC
$0.09
$0.000.54%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 510.83% | -31.78% | -39.53% | -68.10% | 134.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 507.67% | -31.68% | -39.53% | -72.25% | 45.59% |
| Operating Income | -507.67% | 31.68% | 39.53% | 72.25% | -657.24% |
| Income Before Tax | 66.95% | 175.63% | 23.34% | 17.27% | -8,303.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 66.95% | 175.63% | 23.34% | 17.27% | -8,303.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -0.30% | -1.32% | -1.50% | -2.90% | -9.43% |
| Net Income | 68.30% | 232.46% | 26.91% | 18.36% | -2,966.00% |
| EBIT | -507.67% | 31.68% | 39.53% | 72.25% | -657.24% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 69.14% | 240.00% | 30.00% | 28.57% | -2,800.00% |
| Normalized Basic EPS | -1,400.00% | 266.67% | 0.00% | -12.50% | -125.00% |
| EPS Diluted | 69.14% | 220.00% | 30.00% | 28.57% | -2,800.00% |
| Normalized Diluted EPS | -1,400.00% | 233.33% | 0.00% | -12.50% | -125.00% |
| Average Basic Shares Outstanding | 4.70% | 1.67% | 2.01% | 16.18% | 2.39% |
| Average Diluted Shares Outstanding | 4.70% | 12.75% | 2.01% | 16.18% | 2.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |